Abstract:Background: The amplification of the MYCN gene is one of the most powerful adverse prognosis factors in neuroblastoma, but the clinical significance of an enhanced expression of MYCN remains controversial. To reassess the clinical implications of MYCN amplification and expression in neuroblastoma, the status of amplification and the expression level of the MYCN gene of primary neuroblastoma samples were analyzed using highly sensitive analyses. Methods: Using a quantitative polymerase chain reaction (PCR) method (TaqMan), the gene dosages (MYCN/p53) of 66 primary neuroblastoma samples were determined. In all 66 samples, the status of MYCN amplification has been determined previously by the Southern blotting method. Of the 54 samples with a single copy of MYCN based on the Southern blotting method, 23 samples were analyzed for MYCN amplification using the fluorescence in situ hybridization (FISH) method. The expression levels (MYCN/GAPDH) of 56 samples were determined by a quantitative reverse transcriptase (RT)-PCR method. Results: Of the 54 samples with a single copy of MYCN based on the Southern blotting method, 46 samples showed MYCN gene dosages of less than 2.0, whereas the remaining 8 samples with dosages of more than 2.0 were tumors from patients with advanced-stage disease. The results of FISH supported the fact that these 8 samples contained a small number of MYCN-amplified cells. The cases of MYCN gene dosages of more than 2.0 were significantly associated with all other unfavorable prognostic factors (an age of >1 year at diagnosis [P <.0001], nonmass screening [P =.0003], advanced stage [P <.0001], diploid or tetraploid [P <.0001], and a Shimada unfavorable histology [P <.0001]). MYCN gene dosages of more than 2.0 were significantly associated with a high expression of MYCN (P =.0459). However, the expression level of MYCN was not significantly associated with any other prognostic factors. Conclusions: Quantitative PCR may thus be a useful modality for performing a highly sensitive and accurate assessment of the amplification and expression levels of the MYCN gene. In particular, the combination of the quantitative PCR system and the FISH method is considered to be a highly effective method for evaluating the status of MYCN amplification. In this highly sensitive analysis, MYCN amplification (MYCN/p53 > or = 2.0) was reconfirmed to be a strongly unfavorable factor, whereas the expression level of MYCN does not appear to be an independently significant prognosis factor.

Up-regulated Expression of MYCN Gene Induce Apoptosis and Chemo-Sensitivity of Neuroblastoma Cell

Induction of Apoptosis in Neuroblastoma Cell Line SK-N-BE(2) by Modified Expression of MYCN Gene

Suppression of MYCN Gene Expression by Sirna Induced Apoptosis to Neuroblastoma Cells

MYCN gene silence enhance TRAIL induced apoptosis in MYCN amplified NB cell line SK-N-BE(2)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63

Anti-cancer Effect of Oncolytic Adenovirus-Armed Shrna Targeting MYCN Gene on Doxorubicin-Resistant Neuroblastoma Cells.

DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells.

Linking of N-Myc to Death Receptor Machinery in Neuroblastoma Cells

[Effects of NANOG Gene Down-Regulation on the Apoptosis of T-cell Acute Lymphoblastic Leukemia Cells].

Increase in DNA Damage by MYCN Knockdown Through Regulating Nucleosome Organization and Chromatin State in Neuroblastoma

Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma

CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of <i>MYCN</i>-amplificated neuroblastoma

Low Expression of MYCN Promotes Cisplatin Resistance by Suppressing Cisplatin-Induced Apoptosis in Epithelial Ovarian Cancer.

MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent

Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis

Comprehensive analysis and validation reveal potential MYCN regulatory biomarkers associated with neuroblastoma prognosis

MYCN Amplification and ATRX Mutations Are Incompatible in Neuroblastoma

Targeting Mycn Ires in Mycn-Amplified Neuroblastoma with Mir-375 Inhibits Tumor Growth and Sensitizes Tumor Cells to Radiation

MYCN Promotes the Expansion of Phox2B-Positive Neuronal Progenitors to Drive Neuroblastoma Development

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination

Prominent Staining of MYCN Immunohistochemistry Predicts a Poor Prognosis in MYCN Non-Amplified Neuroblastoma